Story perspectives

Novo Nordisk Struggles Amid Investor Doubts and Competition

1/1/2026

43 6

Summary

Story summary

Novo Nordisk faces a difficult move into 2026 as investor confidence wanes after a poor year, with stock plunging on guidance cuts and Eli Lilly competition.
The U.S. approval of Wegovy in pill form has spurred optimism, with shares rising 10% and analysts forecasting market-share gains.
The administration of U.S. President Donald Trump has pressured drug prices, shaping Novo Nordisk's pricing strategies while it pursues new products and direct-to-consumer channels.

1 of 1

Story summary

Novo Nordisk faces a difficult move into 2026 as investor confidence wanes after a poor year, with stock plunging on guidance cuts and Eli Lilly competition.
The U.S. approval of Wegovy in pill form has spurred optimism, with shares rising 10% and analysts forecasting market-share gains.
The administration of U.S. President Donald Trump has pressured drug prices, shaping Novo Nordisk's pricing strategies while it pursues new products and direct-to-consumer channels.